Common stock, $0.01 par value per share
- Symbol
- SMMT
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Summit Therapeutics Inc.
SMMTNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On November 4, 2026, Summit Therapeutics Inc. (the “Company”) filed a prospectus supplement to its automatic shelf registration statement on Form S-3 (Registration No. 333-296642) with the Securities and Exchange Commission.…
Company context
Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Summit was founded in 2003 and the company’s shares are listed on the Nasdaq Global Market (symbol “SMMT”). Summit is headquartered in Miami, Florida, with additional offices in Palo Alto, California, Princeton, New Jersey, Dublin, Ireland, and Oxford, UK.
Current securities
Historical securities (1)
Recent company filings
Registered securities in this filing
Summit Therapeutics Inc. · 8-K · Filed 2026-11-04
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On November 4, 2026, Summit Therapeutics Inc. (the “Company”) filed a prospectus supplement to its automatic shelf registration statement on Form S-3 (Registration No. 333-296642) with the Securities and Exchange Commission. This Current Report on Form 8-K is being filed for the purpose of filing the opinion of Baker & Hostetler LLP relating to the legality of the issuance the shares of common stock of the Company set forth in the prospectus supplement, which opinion is filed as Exhibit 5.1 hereto.